Zepp Health Reports Strong Q4 & FY25 Revenue Growth, Record Margins, and Narrowed Losses; Issues Positive Q1 2026 Outlook

summarizeSummary

Zepp Health reported strong Q4 and full year 2025 financial results, including significant revenue growth, record gross margins, and a substantial reduction in net losses, alongside positive revenue guidance for Q1 2026.

check_boxKey Events

• Strong Q4 and Full Year 2025 Revenue Growth

  Fourth quarter 2025 revenue reached US$85.2 million, representing 43.0% year-over-year growth. Full year 2025 revenue grew 41.8% year-over-year to US$258.9 million, driven by Amazfit-branded products.

• Record High Gross Margin Achieved

  Gross margin for Q4 2025 reached a company-record level of 40.4%, an impressive expansion of 3.6 percentage points year-over-year, primarily due to a favorable product mix and sustained pricing power.

• Significant Reduction in Net Loss

  GAAP net loss for Q4 2025 narrowed by 70.2% year-over-year to US$11.0 million, and adjusted net loss narrowed by 71.6% to US$6.4 million. Full year adjusted net loss decreased from US$56.7 million in 2024 to US$31.5 million in 2025.

• Positive Q1 2026 Revenue Guidance

  Management expects net revenues for the first quarter of 2026 to be between US$50.0 million and US$55.0 million, representing a year-over-year increase of approximately 30% to 43%.

auto_awesomeAnalysis

Zepp Health Corporation delivered robust financial results for Q4 and full year 2025, showcasing significant operational improvements and strong growth momentum. The company achieved substantial year-over-year revenue growth, reaching a record-high gross margin, and significantly narrowed its net losses. The positive revenue guidance for Q1 2026, coupled with a healthy cash position and ongoing debt optimization, indicates a strong trajectory for the company. Investors should note the successful execution of its margin-expansion strategy and the strategic shift towards premium products, which are driving these positive trends.